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This review discusses the potential application of bacterial viruses (phage therapy)
toward the eradication of antibiotic resistant Pseudomonas aeruginosa in children with
cystic fibrosis (CF). In this regard, several potential relationships between bacteria
and their bacteriophages are considered. The most important aspect that must be
addressed with respect to phage therapy of bacterial infections in the lungs of CF
patients is in ensuring the continuity of treatment in light of the continual occurrence
of resistant bacteria. This depends on the ability to rapidly select phages exhibiting
an enhanced spectrum of lytic activity among several well-studied phage groups of
proven safety. We propose a modular based approach, utilizing both mono-species
and hetero-species phage mixtures. With an approach involving the visual recognition
of characteristics exhibited by phages of well-studied phage groups on lawns of the
standard P. aeruginosa PAO1 strain, the simple and rapid enhancement of the lytic
spectrum of cocktails is permitted, allowing the development of tailored preparations for
patients capable of circumventing problems associated with phage resistant bacterial
mutants.
Keywords: choice of phage, Phage therapy organization, cystic fibrosis, phage–host interactions, Pseudomonas
aeruginosa, modular phage compositions, personalized phage therapy
INTRODUCTION
The use of antibiotics in the treatment of bacterial infections increasingly encounters difficulties
caused by the emergence and rapid spread of pathogenic bacteria exhibiting multidrug resistance.
The discovery and study of new antibiotics, is an extremely expensive and arduous process,
associated with many risks (Fowler et al., 2014). As a result there is renewed interest in phage
therapy – the use of bacterial viruses (phages), in their role as “natural enemies” of the bacteria.
The main objective of phage therapy is the elimination of pathogenic bacteria within the foci of
infection. But following the emergence and multiplication of phage-resistant bacteria, the only way
forward will be through the use of new phages capable of overcoming this resistance.
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Phage therapy was proposed and implemented for treating
bacterial infections by Felix D’Herelle, one of the pioneers of
bacterial viruses about 100 years ago. Affirmation as to the
potential medical application of bacteriophages has been
demonstrated by their prolonged use in the treatment of certain
bacterial infections in Russia, Georgia, and Poland. Indeed,
there is particular promise with respect to both the efficacy and
safety of phage therapy toward superficial infections of skin and
mucus membranes (Abedon et al., 2011; Krylov, 2014). In these
countries therapeutic mixtures active against a variety of bacterial
pathogens are produced on an industrial scale, so a significant
level of expertise and a large collection of bacteriophages
have been accumulated over the years. However, widespread
acceptance of phage therapy is far from being achieved. The use
of phage therapy in Western countries mostly ceased following
the introduction of antibiotics into medical practice but now, due
to the emergence of pathogenic bacteria resistant to all available
antibiotics the need for a revival seems almost inevitable.
Scientific professionals are well aware of the epidemic
potential of rapidly spreading multidrug resistance. This
understanding has led to a detailed discussion regarding the
need to implement the use of phage therapy in the medical
practices of different countries and in providing solutions
to the outstanding problems associated with such practices
(Alavidze et al., 2016). Among them are problems of a legislative
nature, the need to prove the long term safety of phage
therapy, promoting the recognition of phage therapy beyond a
handful of Eastern European countries to an international level,
issues with the production of phage cocktails on an industrial
scale, the financing associated with this, and problems with
patenting.
Whilst the need to address these problems is recognized,
one should bear in mind that the future will bring with it
cases in which phages may be the only route to antibacterial
therapy. An example of such a situation could involve the
appearance of plasmids conferring bacterial resistance to colistin
in specialized centers for the treatment of patients with cystic
fibrosis (CF), resulting in a significantly worsened prognosis.
Therefore, the problems associated with the implementation of
phage therapy for the control of multidrug resistant Pseudomonas
aeruginosa requires an immediate solution. In cases where
repeated infections are inevitable (e.g., in CF patients), and
no appropriate antibiotics are available, phage therapy may
prove to be the only option to prolong the life expectancy of
patients.
In parallel to this work, we believe in making the study of
phage therapy in children suffering from CF a priority area.
Success in such cases will secure a place for phages in our
medical arsenal by establishing a positive public perception for
the treatment along with the experience that will be accumulated
in the course of the studies.
Here various aspects required for the implementation of
phage therapy for P. aeruginosa pulmonary infection in children
suffering from CF are discussed in detail. In the age of growing
antibiotic resistance, phage therapy may prove to be the only
feasible route to antibacterial therapy.
FEATURES OF CYSTIC FIBROSIS DUE
TO BACTERIAL INFECTION
Cystic fibrosis is a frequent hereditary disease of Caucasians.
Various estimates have placed on average one out of every
2500 – 7000 newborns as being homozygous for the mutant
allele CFTR1F508. The pathogenesis of the disease is associated
with impaired secretory function of the pulmonary epithelium,
leading to the disruption of ion exchange and accumulation of
mucus and fluid in the lungs. This creates favorable conditions
for the growth of bacteria of various species. At the early
stages, staphylococcal infection is the major culprit, followed by
P. aeruginosa domination (Kosorok et al., 2001). The production
of alginate by these bacteria, an extremely viscous polysaccharide,
by these bacteria promotes the proliferation and survival of
other hazardous species, such as Burkholderia sp., worsening
the overall prognosis (Henry et al., 1992; Lynch and Dennis,
2012). Symptoms of this disease may differ significantly amongst
individuals but the major ones tend to be obvious from a young
age.
During the course of infection a gradual change in the
properties of the primary infecting strains of P. aeruginosa
takes place, manifested by a decrease in their pathogenicity and
virulence, as well as increased sensitivity to the lytic effect of
bacteriophages (Friman et al., 2013; Cullen et al., 2015). Moreover
these strains, being adapted to the conditions of the lungs, are
influencing the expression of the pathogenic properties of other
species in the concomitant microflora (such as Burkholderia
multivorans, Burkholderia cenocepacia, Pandoraea pulmonicola
and Pandoraea apista) significantly lowering them.
It has been proposed that such domination is accomplished
through gene products involved in quorum sensing and
pyoverdine biosynthesis (Costello et al., 2014). The gross activity
of the set of interacting bacteria leads to the destruction of the
lungs, generally seen as the major reason for the reduction in
life expectancy of CF patients. The use of new antibiotics as
well as inhalation protocols for their introduction into lungs
has significantly increased patient life expectancy. However, the
use of antibiotics, even in high doses does not always lead to
the eradication of P. aeruginosa due to the persistence of some
bacterial cells through their transformation into dormant cyst-
like and non-culturable cells (Mulyukin et al., 2015).
An important factor in the evolution of P. aeruginosa in
specialized CF treatment centers is a constant inclusion of
new bacterial strains carrying different prophages in their
genomes, including transposable phages through cross-infection
of patients. It is believed that the activity of the transposable
phages in pathogenic islands has led to the emergence of strains
exhibiting enhanced virulence, pathogenicity and resistance to
environmental factors and, as a consequence, the capability for
epidemic spread (Winstanley et al., 2009). Such epidemic spread
is also a risk factor outside the CF centers (Mohan et al., 2008).
The different approaches were proposed to extend the life of
patients and to improve its quality. Among them is the surgical
replacement of patient’s lungs (Morrell and Pilewski, 2016). There
was also hope to develop a drug for selective inhibition of alginate
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synthesis in bacterial cells (Hershberger et al., 1995). Another
proposition was to substitute the function of the mutant gene, by
creating a viral integratable vector carrying the wild-type allele
(Yan et al., 2015). There is also a suggestion that modification
of the activity of toll-like receptors and other coreceptors with
genetic engineering may lead to changes in critical components of
CF immunobiology. It is not yet possible, but is expected that with
improvements in bioengeneering, that the development of novel
vectors and methods of delivery, biocompatibility, and safety,
then therapeutic effectiveness will be successfully achieved. This
however, could take many years (Atkinson, 2008). Thus, one must
assume that at the present time, and in the immediate future,
antibacterial therapy will be the major approach to treat CF
patients. This currently takes the form of “aggressive antibiotic
therapy,” usually by alternating two antibiotics in order to reduce
the probability of the occurrence and accumulation of multidrug-
resistant mutants. In cases involving resistant strains arising,
there is the option to utilize the inhalation of colistin as a
last resort, a very toxic substance exhibiting a strong surface
activity. Resistance to colistin due to mutations in the bacterial
chromosome is a rare event because it requires mutations in two
genes controlling the structure of the bacterial plasma membrane
(Fernández et al., 2010; Lee et al., 2014), and there was a hope that
the inhalation of colistin may be a reliable protective measure in
adults (for children, in the light of its high toxicity, this is possible
only after the child reaches 6 years age).
Recently, however, a new problem has arisen that may limit
the use of colistin. A transmissible plasmid has been isolated
encoding MCR-1, an enzyme that transforms the bacterial lipid
A in the outer membrane to a colistin resistant state (Liu et al.,
2015). This plasmid has been found in Escherichia coli strains, but
given the relatively ease of interspecies migration for plasmids it
is almost inevitable that a situation will arise when some strains
of P. aeruginosa infecting patients with CF will acquire additional
transmissible resistance to colistin. It is unclear yet corrected
whether a strain with such a plasmid could be displaced by a
more physiologically active but colistin-sensitive strain in the
absence of the antibiotic selective pressure, as sometimes happens
in the case of chromosomal resistance to colistin. Therefore, it is
possible that the use of bacterial viruses – phage therapy – may
not only be suitable, but also a valuable method of antibacterial
therapy, especially in the treatment of children in specialized CF
departments, under careful medical and microbiological control.
COMPARISON OF BACTERIOPHAGES
AND ANTIBIOTICS AS ANTIMICROBIAL
AGENTS: EVALUATION OF RESULTS IN
THE APPLICATION OF PHAGE THERAPY
Bacteriophages acquire the properties of living systems in
the process of infecting sensitive bacteria. There are different
viewpoints about the relations between phages and their hosts.
They are often considered enemies of bacteria, but one can
also look at them from the perspective of being a potential
source of additional genetic material designed to maintain the
evolution of the bacterial domain and their adaptive potential.
In either instance, their natural purpose is not for use in the
treatment of human and animal diseases Thus, it is evident the
desire do not use as therapeutics the phages with substantial
potential to transduce bacterial genes. It is necessary to bear
this in mind in the application of phage therapy and this is
one reason why the outcome of such treatment can be of
an unpredictable nature. Additionally, we cannot preclude the
possibility of events such as recombination with related phages,
the appearance of different phage resistant bacterial mutants, or
the establishment of pseudolysogeny (Hobbs and Abedon, 2016)
in sensitive bacteria, and interactions with different plasmids,
temperate, and virulent phages of unrelated species. Knowledge
of possible modifications in relations of virulent phages and
bacterial hosts is very important for success of phage therapy.
That requires prior conduction of in vitro comparative studies of
the growth of different phages infecting different clinical isolates
in microbiotas.
So how do we evaluate the effectiveness of phage therapy?
When treating open infected wounds using bacteriophages, even
a single use of an appropriately selected phage mixture is
sometimes sufficient (Voroshiliova et al., 2013) for successful
cleansing of the wound. Objective assessment of antibacterial
phage therapy in the treatment of pulmonary infection can be
made by comparing the changes in bacterial compositions in
the sputum of patients before and after phage application (cited
in Abedon, 2015), with evaluation of the resistance of surviving
bacteria to the therapeutic phages utilized (see later). This is
important, as the emergence of resistant variants provides a
level of confirmation as to the success of the previous phage
inhalation treatment, but on the other hand, demonstrates the
need to continue treatment with the selection and introduction
of new active mixtures of phages. Sometimes the effect of phage
therapy can only be observed after several days to allow the
accumulation of an active phage concentration sufficient to infect
most pathogenic cells. In addition, evaluation of the effectiveness
of phage therapy may be valid only in conditions preventing
cross-infection of the patient with other strains that are currently
circulating in the hospital.
PREREQUISITE FOR SAFE PHAGE
THERAPY – REFUSING TO EXPAND THE
LYTIC SPECTRUM OF PHAGE
PREPARATIONS WITH RANDOM
BACTERIOPHAGES
In Eastern European countries where phage therapy is officially
recognized, the decision on its application is taken by medical
practitioners. Factories located across Russia are producing phage
preparations active against several regionally chosen species
of pathogenic bacteria. With a certain periodicity, the phage
preparations are going through a process of “adaptation” to
novel circulating phage resistant strains derived from various
specialized clinics and hospitals of the region by the introduction
of new phages into them from external sources to overcome
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this resistance. This method of enhancing the lytic spectrum
of phage commercial preparations is simple, fast, inexpensive,
and yet very effective (Voroshiliova et al., 2013). Even though
the newly introduced phages have not been identified and their
properties remain unexplored, these preparations show good
results in the short-term treatment of various open infected
wounds, intestinal, and urinary tract infections. The composition
of the phage preparations having a similar designation, but
produced by different manufacturers at different times, may differ
in their activities. This non-identical nature of phage preparations
of varying origin can allow for performance comparisons to be
made and subsequently allow one to choose the most appropriate
mixture. Generally speaking, however, doctors only consider the
possibility of utilizing phage therapy after repeated failures with
different antibiotics (and even then not always!). Nevertheless,
the use of such preparations of random enrichment, containing
uncharacterized phages, including temperate, transposable and
filamentous ones potentially involved in promoting the evolution
of bacterial pathogens in CF can lead to undesirable consequences
(McCallin et al., 2013).
In the course of treating chronic infections, the introduction
of new active phages should take place in real time, in order to
prevent the occurrence and accumulation of new phage-resistant
variants. It is advisable to consider the possibility of modifying
the composition of a medicinal mixture, in which the probability
of occurrence of such undesirable effects could be eliminated or
substantially reduced. This would help transform phage therapy
from an almost forgotten in official medicine procedure with
limited use into an established method for antibacterial therapy
(beyond the realms of CF). First of all, it is necessary to prohibit
the expansion of the lytic spectrum when introducing a mixture
of new phages with unexplored properties. Then, it would also
be desirable that the procedure for adaptation of activity of
the phage mixture be applied to the treatment of an individual
patient and that this is carried out within a clinical setting. Such
modification does not require the introduction of significant
organizational changes, and this work could be accomplished
by existing professional staff of the microbiology laboratory at
the clinic that possess some practical experience working with
bacteriophages. Their task will be to monitor whether phage-
resistant strains arise in patients and to then select new phages
from a phage bank to restore the therapeutic activity of the phage
mixture.
Since in the absence of active antibiotics, phage therapy could
become a permanent clinical procedure, it is important to keep
in mind that some unpredictability can arise that could affect the
outcome of each phage application. Bacteriophage multiplication
in lungs may depend on many uncontrollable conditions –
interactions of different species of bacteria, the nature of the
infected surface, lung fluid composition and viscosity, amongst
other variables.
A critical factor in order to support uninterrupted treatment
time is the permanent expansion of the lytic spectrum of
phage preparations. Therefore, it is of the utmost importance
that rigorous monitoring procedures are established so as to
hastily detect potential phage resistant mutants, as their rapid
eradication may be concentration dependent. Up until now, the
presently adopted procedure for expanding the range of lytic
activity is ineffective, as adaptation demands too much time.
Optimization of lytic spectra for phage therapy, however, should
be personalized in real time. Naturally, it not only increases the
demands on the reliability of the active phage preparation, but
also transforms clinical phage therapy in the ongoing research.
As an example - in medical preparations temperate phage and
their lytic variants, even those possessing unique lytic spectra,
should be absent. Indeed, potential transitions to the prophage
state (as a result of recombination with phages already present
in the lungs) can result in the imparting of properties such as
heightened pathogenicity, increased stability in the environment,
and capacity for epidemic spread.
We believe that an absolute prerequisite for the
implementation of phage therapy worldwide as a method
of antibacterial therapy in CF is the investigation of genetic and
other properties of phages administered into the preparations
and potential interactions associated with these. One can
expect that such work in prospect will provide valuable new
data required not only for the characterization of phages as
antibacterials but also, for example, as the carriers of genetic
material capable of compensating the CFTR gene mutation
responsible for CF.
Numerous studies have been carried out with the end goal of
achieving the resurrection of phage therapy within the Western
world, including the treatment of CF associated infections.
Various models of acute and chronic infection in mice, rats,
wax moths, and cell culture provide an excellent framework for
testing phages under a variety of conditions. For example, it
has previously been demonstrated that the use of wax moths
(Galleria mellonella) as a model allows one to carry out rapid
comparisons of phage activity, useful for making swift evaluations
of effectiveness with respect to particular phage preparations
in vivo during the treatment process (Beeton et al., 2015; Olszak
et al., 2015). Using a mouse model, it is also possible to estimate
bactericidal activity by lytic phages in lung infection. One study
has shown a good correlation of activity in vitro and in vivo
for all virulent phages utilized, however, with the exception of
two species, shown as being insufficiently active in vivo despite
good in vitro activity (Henry et al., 2013). This is a significant
observation as it highlighted the need to increase the lytic activity
in phages of several species through the selection of specific
mutants displaying enhanced virulence. This also demonstrates
the need to develop optimal configurations for phage mixtures,
so as to achieve the best treatment outcomes. Indeed, with respect
to the utilization of multi phage preparations, the therapeutic
activity is a product of the combined effect of all phages present.
In fact, Alemayehu et al. (2012) previously demonstrated the
ability to stop a primary infection of mice with a multidrug-
resistant P. aeruginosa strain taken from a CF patient with lung
infection with such phage preparations. The bactericidal effect of
these phages has been confirmed with an in vitro infection of this
strain on a CF biofilm bronchial epithelial (CFBE41o) cell line. In
addition to all of this, application of two strain specific virulent
phages in a murine model of acute pulmonary P. aeruginosa
infection was accompanied not only by rapid elimination of
the pathogen, but by a concomitant decrease in the level of
Frontiers in Microbiology | www.frontiersin.org 4 October 2016 | Volume 7 | Article 1631
fmicb-07-01631 October 7, 2016 Time: 15:23 # 5
Krylov et al. Modular Approach to Selection of Phages
inflammation (Pabary et al., 2015). However, the requirement
for continuous monitoring of lung composition in CF patients
during the application of phage therapy is essential, as is the need
to take additional measures in order to prevent the permanent
adhesion of bacteria to the pulmonary epithelium. Friman et al.
(2016) demonstrated that individual pre-adaptation of a phage
for a different patient increases the efficiency of the phage killing
effect. However, conducting this pre-adaptation process may take
some time and delay the onset of the actual treatment, which is
obviously not always possible. In light of all this research, it is
clear that there is significant promise for the implementation of
phage therapy in the treatment of CF associated infection and no
doubt beyond this, however, rigorous protocols must be set in
place if we are to ensure both the safety and maximum potential
of treatment.
Significance of Temperate
Bacteriophages in CF Clinical
Manifestations
Studies using metagenomic analysis have shown how temperate
bacteriophages of P. aeruginosa in clinical conditions following
induction become involved in the horizontal transfer of DNA,
and acquire selective preference for the development and
accumulation in the specific conditions of the lower lung (Tariq
et al., 2015). Their ability for transfer of additional genes increases
with time during the deterioration of patient lung function
and disease prognosis. This represents the first, direct clinical
confirmation for the proposed evolution of phages in vivo at
mucous lung surfaces. The active role of phage gene expression
in the course of the disease and its prognosis has been confirmed
in a study involving the Liverpool epidemic strain. Other research
(Lemieux et al., 2016) has shown that groups of strains possessing
mutations in prophage regions and pathogenic islands displayed
reduced pathogenicity in a rat model of chronic lung infection
and was associated with disturbances in phage transcription.
Critical Analysis of the Results of Phage
Therapy in Pseudomonas aeruginosa
Infections for a Group of Children With
Cystic Fibrosis
The predominant goal of antibacterial therapy in CF is to cure
chronic bacterial infections, especially those due to P. aeruginosa,
with the aim of increasing patient life expectancy. This is of
paramount importance in children up to 6 years of age, due to the
inability to utilize colistin in extreme cases of multidrug resistant
infection. Phage therapy in CF therefore should be implemented
with this group in the forefront of our minds. The significance
of the ongoing research will hopefully result in a resurgence of
interest in phage therapy in the Western world, especially to
support children suffering from CF.
Of relevance is collaborative research that took place in
1991–1992 between the Laboratory for bacteriophage genetics
(being at that time in the Institute for Genetics and Selection
of Industrial Microorganisms, Moscow, Russia), and the
Department of Mucoviscidosis (CF) in the Children’s Republican
Clinical Hospital in Moscow. Following the acquisition of
parental consent and permission from the Academy of Medical
Sciences (Figure 1), a study was conducted into the use of
P. aeruginosa phages in the treatment of five children with
CF. Whilst there were no specific restrictions for the number
of children to be involved in this research, the need to limit
the number of participants was felt as being necessary due to
the fact that this was the first trial involving the inhalation of
phages for the treatment of CF associated infection and prudence
is always wise in such uncharted territory. In addition, the
phage preparations used were tailored and prepared in highly
concentrated forms with purification on cesium chloride density
gradients for participants to use over 7–10 days. Due to these
rigorous protocols, laboratory resources were limited to a small
number of patients.
The five children were aged from 7 to 12 years old. The
compositions of the Pseudomonas strains in their lungs were
studied. The differentiation of strains was performed by taking
into account features such as resistance to clinically used
antibiotics, mucus (alginate) production, colony pigmentation,
temperate phage production, and sensitivity to various
bacteriophages (including temperate) available at that time
in the laboratory collection. Usually at least two different
P. aeruginosa strains were found in the sputum of each child. The
different mixtures of virulent bacteriophages were prepared for
each child based on testing bacterial strain sensitivity to phages.
The phages utilized were chosen among several species classified
at the time, including phiKZ-, Lin68-, and PB1-like phages, and
those of a group referred to later as the phiKMV-like phages. The
phages were selected for each child based on the greatest lytic
effect on strains isolated from sputum (those which resulted in
transparent lysis in the spot assay). Selected phages were grown
overnight in petri dishes with P. aeruginosa PAO1 by confluent
lysis, followed by resuspension into saline and bacterial debris
removed by centrifugation. The supernatant was treated with
chloroform to eliminate residual bacterial cells and phages were
further concentrated by polyethylene glycol precipitation. The
resulting phage were then subjected to centrifugation in a cesium
chloride gradient. Following dialysis, individual preparations
were mixed with titers of at least 1011–1012 particles/ml. Such
high titres were used based on the assumption that a higher
concentration of phages in inhaled mixtures would allow the
determination of an effect (or lack of) in a short period of time.
However, during the actual clinical application of the phage
mixtures the preparations were diluted several times as it was
found that concentrated mixtures were unable to pass through
the inhalation device. The inhalations were carried out over the
course of a week along with the standard monitoring protocols
of the children’s status.
It was found that one child had gone through a short period
involving a transient increase in body temperature. The others
had no obvious changes in their general condition. In two cases,
comparison of bacteria in sputum samples after the course of
phage therapy revealed evident changes attributable to the use
of phages. In one of the sputum samples, were prevailing phage-
resistant variants displaying the appearance exhibited by the
original pigmented bacteria and the typical mucoid properties
observed in P. aeruginosa. In the sputum of the second child
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FIGURE 1 | Official permission for application of phage therapy in CF unit of The Central Republican Children Clinical Hospital, Moscow, Russia and
agreement of physicians in CF unit to collaborate in the study (for request of grant support).
were phage-resistant variants of P. aeruginosa exhibiting novel
properties. It was proposed that in this second case the original
phage sensitive bacterial cells were substituted for another phage-
resistant strain, with the new properties, possibly due to cross-
infection from other patients.
The emergence of phage resistant variants of the initial
infecting bacterial strain in one child and the substitution of
sensitive bacteria for a new phage resistant strain in the lungs
of the second child is clear evidence as to an effect from phage
therapy in vivo. The absence of detectable changes in three other
children could be attributed to various reasons such as too low a
concentration of phage mixture following dilution of the original
formulation, the high viscosity of mucus hindering the spread
of the phage, and insufficient duration of phage application.
These results were presented in several CF meetings and were
considered as initial evidence for the safe use of phage therapy in
CF (Shabalova et al., 1993, 1995). Unfortunately derivative studies
were unable to be carried out at the time due to insufficient
funding opportunities. However, giving the growing antibiotic
resistance, this is starting to change. The use of commercial
preparations of phages in the treatment of P. aeruginosa infection
in children with CF in Georgia also has shown some promise
(Kutateladze and Adamia, 2010).
THE MODULAR COMPOSITION
PRINCIPLE FOR THE PREPARATION OF
THERAPEUTIC PHAGE COCKTAILS
The pediatric study described above showed that personalized
phage preparations can have a noticeable effect on a brief
timescale. The previously active P. aeruginosa strains in lungs
of two children were eliminated and were substituted with
other strains. Independent of their origin (resistant mutant or
cross infection), such situations require immediate re-evaluation
of the therapeutic mixture for each of the two children
showing positive reactions. The use of commercial preparations
containing uncharacterized isolates is not an appropriate course
of action. Therefore, a series of rapid protocols needs to be set in
place to permit the rapid isolation, characterization and choice of
phages and to allow the appropriate modification of preparations
within a therapeutic timeframe. All of this must to be carried out
in a safe and pragmatic manner.
We propose a method to enhance the rate at which phage
mixtures are prepared for personalized therapy in CF through
an alternative approach that will also permit the enhancement of
the lytic spectra of the resulting preparation. The fundamental
idea is to utilize what we refer to here as a modular principle.
These modules may be monospecies phage mixtures or a mixture
of phages of unrelated species taken from a collection of pre-
selected phages. The advantage of this approach is that the
expansion of phage activity of such mixtures has not been
achieved through a one-time introduction of unknown phages
in the final product, but introduction into each such modular
product, a new phage of the same species but with enlarged
activity for monospecies mixtures or some another new phage
into a heterospecies mixture. In a joint multiplication of such
mixtures, closely related phages may recombine, potentially
resulting in progeny exhibiting novel spectra of lytic activity.
Thus, to transition to this novel approach we propose (1) to
select a limited number of well-studied phage groups, containing
a great deal of described non-identical phages and compose
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FIGURE 2 | Different growth appearance on P. aeruginosa PAO1 lawn
permits preliminary identification of five bacteriophage species.
from these phages monospecies mixtures displaying unique
lytic spectra; (2) merge, into a common single multispecies
blend, well studied bacteriophages of other known species, with
unique spectra of lytic activity; (3) Each of the preparations
are propagated through infection of P. aeruginosa PAO1 or
other acceptable strain; (4) The final therapeutic preparation
for personalized therapy is composed of individual mixtures
(modules) to allow for maximal lytic activity.
Obviously, the extensive accumulation and study of phages
for each of the chosen species exhibiting a wide spectrum of
lytic activity is an absolute prerequisite for the operation of this
protocol. As described above, even short-term use of mixtures
of constant composition from a small number of phages leads
to the selection of resistant bacteria. Up until now there are
only individual studies on the frequency of phages capable
of infecting different bacterial species. For example, there is
a report describing phages capable of infecting the bacterial
species P. aeruginosa and Burkholderia cepacia (Nzula et al.,
2000). But it is important to consider and evaluate potential
interspecies transduction in such instances. In another study
(Malki et al., 2015), the authors demonstrate that PB1-like
phages of P. aeruginosa isolated from a natural habitat can
infect unrelated species of the Arthrobacter, Chryseobacterium,
and Microbacterium genera. It also suggests the possibility of
interspecies transduction with potentially unpredictable results.
Of course, despite this possibility, this is a natural inevitability
associated with bacteriophages, and is independent of the phage
therapy process (Penadés et al., 2015). Complete prevention is
therefore not a realistic goal. However, we believe that additional
studies are necessary to gain an insight into the effect of
horizontal gene transfer with in vivo applications of phages.
Of critical significance in the selection of phage species for
treatment of pseudomonade infection in CF is the ability to
infect different natural P. aeruginosa strains. From a practical
standpoint this is achieved through the recognition of such
susceptible strains through the appearance of plaques. Moreover,
in primary pulmonary infections of patients with CF, any strain of
P. aeruginosa is capable of participation. As a general dogma, in
the process of producing future proof therapeutic mixtures, the
best species of phages form the foundation upon which refresh
cycles take place using new modules to expand the overall lytic
activity as necessary. Based on these general considerations and
prior experience, we have chosen three phage groups suitable for
composing integral monospecies phage mixtures as a foundation:
phiKZ-like, phiKMV-like, and PB1-like phages. Their frequent
occurrence in current commercial mixtures may reflect the
broad spectrum of their lytic activity. In addition, they are
well characterized – many genomes of phages in these groups
have been sequenced and annotated. Finally, phages of these
species produce recognizable plaques (Figure 2) making it easy
to identify them amongst mixed populations in natural samples.
There are, however, other phage species which seem promising
for additional monospecies phage mixtures and which form the
basis for subsequent research.
FEATURES OF SPECIES SELECTED FOR
MONOSPECIES PHAGE MIXTURES AND
CHOOSING THE BEST SOURCES OF
THESE PHAGES
Table 1 lists the general characteristics of a group of selected
virulent phage species active on P. aeruginosa (Adams et al.,
2015). The function of most gene products of these phages
remains unknown. Therefore, the choice of these phage species
for therapy is based mainly upon the results of long-term
work in several laboratories and, in addition, on the frequent
presence of these phages in commercial therapeutic mixtures,
from the days of D’Herelle. It is possible to assess the efficiency of
different phages by determining their proportionality following
a therapeutic application using plaque phenotype and PCR and
then appropriately adapt the mixture for the next round of phage
therapy. Below is an overview of the major groups of phages
proposed to be utilized within monospecies and heterospecies
mixtures.
The phiKZ-Like Viruses
The phiKZ-like group of giant phages infecting P. aeruginosa
includes several species and are of interest not only because of
their use in a therapeutic setting, but also as a unique model
for the study of phage evolution and specific packaging of the
genomic DNA (Burkal’tseva et al., 2002; Mesyanzhinov et al.,
2002; Krylov et al., 2003, 2004, 2005, 2011; Hertveldt et al., 2005;
Shaburova et al., 2008; Pleteneva et al., 2010; Sokolova et al.,
2014). This group of Myoviridae phages includes several phage
species that exhibit common properties of the type member
phiKZ (particle size and morphology, the presence of an inner
body in the capsid, and a specific packaging mechanism of phage
genomic DNA). In sequenced and annotated genomes of two
different species of this group – phiKZ and phiEL, genes encoding
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a DNA polymerase have not been found. This may prove to be
a common feature for this group. The genomes of PhiEL and
phiKZ differ in their sizes and lack any tangible homology at the
nucleotide level. Two other phages closely related with phiEL are
phiRU (isolated from soil) and phiCHE (from a clinical strain
of P. aeruginosa isolated from an infected burn wound). phiEL-
like phages may be crossed in different combinations, giving
rise to viable progeny. This is potentially useful for generating
recombinants displaying variable host specificities both in vitro
and in vivo.
Phages phiLin68 (of Lindberg phage collection) and phiLBG22
(our lab collection) are representatives of the third group in
the phiKZ-like viruses. These phages were included due to
the fact that they can lyse some strains resistant to phages
from the phiKZ and phiEL groups. We have found non-
identical phiKZ-like bacteriophages in all therapeutic commercial
mixtures from different manufacturers. Interestingly, phiEL- and
phiLin68-like phages have not yet been found within therapeutic
mixtures. In creating therapeutic preparations containing phiKZ-
like phages, one should bear in mind that all species in this
group have the ability to transfer bacterial cells into persisting
(“pseudolysogenic”) state (Pleteneva et al., 2010). It has similarity
with effect of lysis inhibition after infection of E. coli bacterial
cells with wild type phage T4 but not with r-type mutants
(rapid lysis) (Doermann and Hill, 1953). A possible reason
may be the maintenance of certain structures in cell envelope
after the re-infection of bacteria with wild-type phage (Krylov,
1970). Meanwhile phiCHE bacteriophage, closely related with
phiEL, has been isolated from a bacterial strain in burn wound.
Different mutations in genomes of phiEL-like phages influence
the effect (Krylov et al., 2011). This is manifested through
the appearance of opalescence of bacterial growth (Figure 3)
and a significant increase in the final yield of phage. In this
state, however, the lysis of infected bacteria is delayed. For this
reason, it is not desirable to use wild type phiKZ-like phages
as components in therapeutic preparations for the treatment of
P. aeruginosa pneumonia. In addition, amongst P. aeruginosa
strains isolated from the lungs of CF patients are often those
strains capable of producing autoplaques (Pillich et al., 1985).
We have found that in vitro infection of clinical isolates in CF
with different wild type phiKZ-like phages leads to a decrease
in the level of autoplaquing of these bacteria. As a result, the
growth of phiKZ-like pseudolysogenic bacteria occurs more
rapidly than the growth of the original uninfected bacteria
(Figure 4). Therefore, to maintain the possibility of using the
wide lytic potential of phiKZ-like phages in CF in a safe manner,
we have isolated a group of mutants in phages phiKZ and
phiEL which have lost the ability to transfer bacteria into the
pseudolysogenic state (Krylov et al., 2011). Some of these mutants
are also showing signs of hypervirulence, capable of lysing
pseudolysogenic bacteria. We believe that mutant phages such
as these, belonging to the phiKZ- like group can be used safely
as part of the therapeutic mixtures, complementing each other’s
activity and thus providing us with an additional weapon in our
arsenal.
The decision to include phages of Lin68 species into a
therapeutic mixture could be made after the isolation of similar
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FIGURE 3 | The vir-mutant of bacteriophage phiKZ is unable to enter the pseudolysogenic state.
FIGURE 4 | The growth of phiKZ and phiCHE pseudolysogens in
places of phages application on the background of auto-lysed lawn of
plaque forming clinical isolate P. aeruginosa CF017 after prolonged
incubation.
mutants and (preferably) after the sequencing and annotation of
their genomes, as done for phiKZ and phiEL.
PhiKMV-Like Bacteriophages
phiKMV – related bacteriophages (Lavigne et al., 2003, 2006;
Burkal’tseva et al., 2006) are also frequent components of the
various commercial mixtures and display different host ranges
and plaque sizes to that of other groups. For example, a new
phiKMV-like phage, phiNFS, has been isolated as a mutant
from a commercial mixture by our group. The parental phage
forms small transparent plaques on the lawn of strain PAO1
and in each such plaque mutants with increased growth rate
have arose at high frequency (Krylov et al., 2015). The possible
reason for this effect may be related with the use of a bacterial
host exhibiting properties that differ from those in P. aeruginosa
FIGURE 5 | The growth of KMV-like phage phiNFS on lawn of plaquing
P. aeruginosa clinical isolate inhibits plaque formation. The different
activities of diffusible products can be observed: (a) complete inhibition of
plaquing; (b) a significant reduction in the size of the plaques to a certain size;
(c) an abrupt discontinuation of interaction. This is an example of a
phage–host interaction which can seriously influence the results of phage
therapy by enhancing bacterial growth in lung biofilm. Only specially prepared
phage mixture can prevent undesirable effects of mono phage therapy.
PAO1 in the production of the commercial mixture. Mutants
isolated from various plaques may vary in growth rate on
different clinical isolates. The ability for permanent modifications
of different growth characteristics is an inherent feature of the
phage phiNFS. The mechanisms underpinning this are under
investigation. Preliminary data suggest that it may be related to
processes involved in quorum sensing. For example, in some
clinical isolates phage phiNFS specifically inhibits the formation
of bacterial plaques with a clear border of inhibition observed
(Figure 5), which can be explained with the production in plaque
growth of an unknown product which interacts specifically with
cells of the plaque producing bacterial strain (“all or nothing”).
This phage displays the greatest expression of a peculiar feature of
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FIGURE 6 | The continuing phiKMV-like phage growth going through
cyclic periods of lytic growth and pseudolysogeny.
FIGURE 7 | The common feature of all PB1-like phages are specific
bacterial bands bordering their plaques. Such bands contain special
bacterial cells in the pseudolysogenic state and which limit the growth of
phages of other species. In some cases this property can influence the result
of phage therapy (a) The growth of cells in pseudolysogenic state around
phiPB1 phage plaque. (b) Interaction of lytic areas of bacteriophages phiPB1
and phiNFS.
the phiKMV-like phages: continuous (5–7 days) growth on aged
bacterial lawns, something uncharacteristic of other species of
P. aeruginosa phages. The cyclic nature of this growth may be due
to the ability of the phage to overcome the physiological changes
in bacteria arising as result of the aging process (Figure 6).
PB1-Like Bacteriophages
PB1-like bacteriophages are another frequent representative of
phage cocktails. A clear plaque with a characteristic feature - a
dark stripe along the edge of the growth (Figure 7a) is a typical
feature of the group and may be used as a species characteristic
in looking for new phages of the group. This stripe appears at the
end of plaque growth and it consists of infected cells in a specific
state (Krylov et al., 2015). It limits the spread of the plaques
of other phage species (Figure 7b) but is unable to prevent
penetration of phage particles into PB1 plaques. Advantages of
the PB1-like phages are in the simplicity of their selection from
enrichment of therapeutic mixtures (non-identical phages can be
often be found in samples taken from the same natural water
sources), a wide range of lytic activity, and a relatively low
frequency of phage resistant mutant generation (Garbe et al.,
2010).
Heterospecies Phage Cocktail
Besides the three monospecies mixtures, we suggest the use of
an additional mixture comprising phages of several unrelated
species. Each of these phages display certain differences in their
spectrum of lytic activity, for example, the ability to lyse bacteria
exhibiting resistance to phage mixtures of the three previously
mentioned major species, as well as strains carrying a plasmids
conferring phage-resistance. This group includes phages phiEL
(NC_007623), phiLin68, phiPerm5, phiMK (KU61955), and
phiCHU (NC_028933), representing several different groups. As
all the phages of those selected for this mixture are relatively
easy to recognize (Krylov et al., 2015) the choice of new
phages for the purpose of expanding the lytic spectrum will
face little in the way of problems. Nevertheless, it is of critical
importance to pay special attention to the possibility of significant
differences existing between closely related phages. Sometimes
their genomes can contain small variations which result in them
being inappropriate for therapeutic use. For example, phages
phiTL and phiCHU showed good growth on PAO1 in the
presence of IncP2 group plasmids (for example, pMG53 plasmid)
and on some clinical isolates resistant to other phages. The
improved growth of phages is accompanied with occurrence of
unstable plaque morphology (Figure 8). However, only phiCHU
can be utilized in therapeutic mixtures as the phiTL genome was
found to encode a putative transposase fusion gene (NC_023583,
Magill et al., 2015). These phages are closely related to LUZ24
(Ceyssens et al., 2008; Wagemans et al., 2015) and phiPaP3 (Tan
et al., 2007), together belonging to the LUZ24likevirus genus.
P. aeruginosa PAO1: THE BEST HOST
FOR THE STUDY OF NEW PHAGES, BUT
NOT FOR THE MULTIPLICATION OF
THERAPEUTIC MIXTURES?
In some cases, problems may arise when trying to find a
suitable strain for the amplification of finalized therapeutic
mixtures. One such problem is that P. aeruginosa strains
often contain the prophages of filamentous phages. The
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FIGURE 8 | Diversity of bacteriophage phiCHU plaques on lawn
P. aeruginosa PAO1 (pMG53). The replanting of phages from clear (a),
turbid (b) or semiclear (c) plaques again leads to production of all types of
plaques. Bar is 1 cm.
reason for the frequent occurrence of filamentous prophages
is believed to be that they provide adaptive capabilities to
P. aeruginosa under unfavorable conditions (Rice et al., 2009).
The accumulation of filamentous phages within the mucus of
the lungs promotes crystallization and establishment of solid
biofilms (Secor et al., 2015). Therefore, choice of hosts containing
these prophages (such as P. aeruginosa PAO1) can result in
the unintentional inclusion of filamentous phages into the final
preparation. The therapeutic use of a phage mixture obtained
as a result of random enrichment and amplification on an
unstudied host strain is therefore undesirable. In addition,
one should note that despite the fact that the PAO1 strain
of P. aeruginosa is a well studied and long standing work
horse of many microbiology laboratories, one should be careful
with respect to its potential use in the final amplification of
phage preparations. This is due to the fact that it possesses
a fairly high pathogenic potential, as seen by its long term
presence within the lungs of mice, though it is advantageous
for the prevention of introducing temperate phages with
undesirable features (Tayabali et al., 2015). It does, however;
remain as the accepted strain for the study of the phages
themselves.
The work on the creation of a reserve collection of new
phages for inclusion into monospecies phage mixtures should
be carried out on an ongoing basis. In accordance with our
experience, the selection of new phages and reproduction of
monospecies mixtures would be better accomplished with the
strict use of the standard strain of P. aeruginosa PAO1 and its
minor variants (e.g., those carrying plasmids for propagation
of plasmid dependent phages such as phiCHU). The use of
the standard strain PAO1 is necessary for preventing the
introduction of potential temperate phages with undesirable
features (for example, transposable capabilities) into therapeutic
phage mixtures. It is evident, joint multiplication of non-
identical but closely related phages can and will produce valuable
recombinants, including ones with an increased spectrum of lytic
activity. Thus the simple act of reproduction of a monospecies
mixture will create an additional opportunity to expand the lytic
spectrum.
“NON-ESSENTIAL” GENES AND THE
PROSPECT OF “CORRECTING” THE
GENOMES OF BACTERIOPHAGES
We are confident that phage therapy of P. aeruginosa infection
in children with CF is a very promising approach and is by
no means limited to the use of natural phages from well-
studied groups. It is likely that novel methods for genome
editing will be utilized in the enhancement of therapeutic phages.
This will permit less time consuming selection procedures
for phages exhibiting novel lytic spectra. It may therefore be
of some interest to investigate the reasons behind significant
differences in genome sizes of phages exhibiting identical
morphologies, due to the presence in the genomes of some
phage species, regions which contain potentially non-essential
genes with accessory functions. Such phages could be used as
convenient vectors. For example, in phages phiKZ and phiEL
which belong to different but phylogenetically related groups of
giant phiKZ-like phages, we observe that phage particle sizes
and the internal volume of the capsid are similar. The genome
of phiEL, however, is ∼80 kb less than that of phiKZ. The
cause of this difference may be, for example, a discrepancy
in evolutionary rates of the morphological structure of the
phage particle and its genome size. One must also consider
that increases in genome size are limited by the capacity of the
phage particle, so it could be reasoned that evolution would
favor smaller genome sizes due to physical constraints. The
viability of phage particles (in particular, the ability of DNA
be injected into cell) though, may depend on the density of
DNA packaging, and the loss of a significant number of genes,
even those whose functions have ceased to be significant in
the development of the phage, could prove lethal. In such
cases there are two different strategies that may permit phage
survival. One such strategy would be the evolution of a novel
DNA packaging mechanism. Another possibility is via the
conservation of genes whose functions become unnecessary or
to replace them by similarly sized DNA sequences of temporal
origin. As it happened, both of these strategies have been
implemented. In the case of phage phiEL a variable packaging
mechanism has arisen, which provides the necessary density
for DNA packing and thus injection (Sokolova et al., 2014).
Another postulated mechanism can be illustrated by comparing
the genomes of two closely related phages of P. aeruginosa
PAO1 – temperate phage phiD3 and its naturally lytic variant
phiPMG1 (Krylov et al., 2012). In the central part of the genome
of these phages there exists a large region containing gene
fragments of variable origin. The presence of extensive areas of
insignificant DNA (“genome gaps”), is an apparently common
phenomenon. They were also found when comparing of the
genomes of two transposable phages, PM105 and B3 (Pourcel
et al., 2016).
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Phages which possess these genome gaps could form
a solid basis for the directed design of therapeutic phage
genomes, for instance to insert genes that increase the
efficiency of phage lysis. For example, the insertion of
genes encoding bacteriocins, capable of killing bacteria
of other pathogenic species, usually associated with CF.
This idea is extremely promising but will require not only
knowledge of the detailed functions of all genes and their
interactions, but also evidence that the introduction of new
genes will not result in adverse unwanted effects. Also,
development and use of such future artificial phages will
require thorough study of their potential interactions with the
natural microbiota in humans and their potential environmental
impacts.
Expanding the Collection of Therapeutic
Phages: National and International
Phage Bank Cooperation
The implementation of continuous personalized phage therapy
will require a cooperative and efficient system to allow the
exchange of specific bacteriophages. The existence of a central
phage bank keeping most of the phages active on P. aeruginosa
and other pathogens active in CF and ensuring their availability
for clinical laboratories in different countries would become an
extremely valuable resource in addition to national collections.
The basic purposes of this central phage bank would be:
(1) The accumulation of P. aeruginosa phages, their
classification and comparison of their specific activities;
(2) Storage of phages which have been certified as safe;
(3) Composing initial monospecies phage mixtures with wide
host range to adapt mixtures for real time requirements in
hospitals;
(4) The delivery to hospitals of small samples of different
phages to help clinicians and laboratory staff carry out the
rapid selection of appropriate phages.
The understanding for the necessity of forming such phage
banks is now generally accepted. Such institutions will form the
central hub from which phage therapy can be developed.
CONCLUSION
One of the purposes of this review was to show that
choosing phages suitable for therapeutic use requires not
only genomics and bioinformatics approaches, but long-term
preliminary studies of their properties and their manifestations
under different conditions in order to optimize their activity.
The other purpose was to introduce a novel approach
for the composition of therapeutic mixtures based upon
a modular assembly of personalized preparations utilizing
combinations of mono- and hetero- species mixtures to
use in the treatment of P. aeruginosa infections in CF
patients.
There is no doubt as to the efficiency of phage therapy
when the correct selection of phage has been achieved. As
discussed, this has been confirmed in experiments involving the
eradication of P. aeruginosa lung infection in mice following
intranasal administration of virulent phages (Alemayehu et al.,
2012; Henry et al., 2013). There is also indirect confirmation of
a positive response to phage activity under clinical conditions
following from the observation (James et al., 2015) whereby
authors found a correlation between increases in the number of
free temperate phage particles in the sputum and improvements
in the patient’s condition. This is understandable, because
infection of bacterial cells with temperate phages usually
results in the lytic cycle being the predominant mode of
phage development. However, this study does not support the
deliberate use of temperate phages. Finally, an example of the
direct use of personalized phage mixtures in clinical practice
described here reinforces the overall safety of the procedure
itself.
Thus, we believe that phage therapy in CF is promising,
but its use should be limited to those special cases whereby
all available antibiotics have been proven to be ineffective. The
group of potential patients includes children up to 6 years of
age infected with multi-resistant strains of P. aeruginosa (as the
use of colistin is not yet permitted) or adult patients infected
with P. aeruginosa resistant to all available antibiotics, including
colistin. As a matter of fact the transition to the permanent
use of phage therapy, even in special cases, will require a
significant change in the workings of specialized clinics. There
must be special measures in place to separate the patients under
phage therapy from others so as to prevent cross infection
with other P. aeruginosa strains. The best solution would be
the organization of a special center of phage therapy for CF
patients, providing necessary resources and the capability to
support and enlarge phage collections, etc. The work of personnel
in such centers will include procedures utilized on a daily
basis in academic laboratories. The aim of specialized teams
of microbiologists in hospitals working with phages will be to
monitor the changes in the proportion of bacteria resistant
to used phages, developing and scheduling the introduction
of new phage preparations, creating new combinations of
compounds that extend the lytic spectrum, all procedures that
should ensure the continuity of phage therapy. We believe
that if certified manufacturers of commercial phage mixtures
were to participate in the preparation of proposed mono-
and heterospecies phage mixtures, it would both simplify and
greatly in diminish the response time in the preparation of
personalized cocktails and thereby help phage therapy become
established as a major weapon in our arsenal against bacterial
infection.
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